Innovair

Beclometasone dipropionate and Formoterol fumarate, the active ingredients in Innovair, are an inhaled corticosteroid/long‑acting β2‑agonist presented as a fixed‑dose inhalation aerosol for inhalation use. The combination treats asthma and chronic obstructive pulmonary disease (COPD) as a maintenance therapy in adults and adolescents who require regular control of airway inflammation and bronchodilation.

GNH USA supplies Innovair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innovair is indicated for chronic respiratory diseases where airway inflammation and bronchoconstriction require long‑term control.

Asthma: improves symptom control and reduces the frequency of exacerbations in patients needing maintenance therapy. COPD: provides sustained bronchodilation and anti‑inflammatory effects to help prevent worsening of symptoms and exacerbations. Severe asthma: used as step‑3 or step‑4 therapy when inhaled corticosteroid alone is insufficient.

Like all inhaled corticosteroid/LABA combinations, Innovair may cause a range of adverse reactions.

Common Side Effects: - Throat irritation or soreness - Hoarseness or voice changes - Oral candidiasis (thrush) - Cough or wheeze after inhalation - Headache - Tremor or shakiness

Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression with prolonged use - Decreased bone mineral density - Allergic reactions including anaphylaxis - Pneumonia, especially in COPD patients - Cardiac arrhythmias or tachycardia

Before prescribing Innovair, clinicians should evaluate patient‑specific risk factors and provide guidance on proper use.

Assess infection risk: evaluate for active respiratory infections before initiating therapy. Monitor growth: in pediatric patients, regularly assess growth velocity. Screen for tuberculosis: consider testing prior to long‑term corticosteroid use. Avoid abrupt discontinuation: taper if therapy is stopped after prolonged use. Use spacer device: to reduce oropharyngeal deposition and local side effects. Store below 25°C: keep in the original pack, protect from moisture and heat.

Innovair may interact with several drug classes; careful assessment is required.

Major Interactions (Avoid): - Beta‑blockers: may reduce bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase systemic exposure to formoterol. - MAO inhibitors: may enhance sympathomimetic effects of formoterol. - Other inhaled corticosteroids: increase risk of systemic corticosteroid effects. - Diuretics: may potentiate hypokalemia caused by β2‑agonists.

Moderate Interactions (Monitor Closely): - Ritonavir: may raise formoterol levels, monitor for tachycardia. - Theophylline: additive stimulant effect on the heart, observe for arrhythmias. - Diabetes medications: β2‑agonists can raise blood glucose, adjust monitoring. - Anticholinergics: combined bronchodilation may increase risk of dry mouth. - Live vaccines: consider timing due to immunosuppression risk.